Sobetirome: a selective thyromimetic for the treatment of dyslipidemia.

Abstract

Atherosclerosis and its clinical sequelae still represent the primary cause of death in Western societies. During the past 25 years, a novel drug class to treat dyslipidemia, a main risk factor for coronary artery disease, emerged: liver- and thyroid hormone receptor isoform β-selective analogs. The present review will discuss the recent patents applied for sobetirome (GC-1), which set the course for the establishment of a novel approach to lower plasma cholesterol and triglycerides. We will focus on the major mechanisms conferring sobetirome lipid-lowering properties, including the induction of hepatic LDL receptor, the promotion of the so-called reverse cholesterol transport, and finally the induction of bile acid production and biliary sterol secretion. In summary, thyromimetics such as sobetirome may represent a useful treatment for combined hyperlipidemia, which is associated with a major cardiovascular risk.

• Authors: Ivan Tancevski, Egon Demetz, Philipp Eller
• Journal: Recent patents on cardiovascular drug discovery (Recent Pat Cardiovasc Drug Discov) Vol. 6 Issue 1 Pg. 16-9 (Jan 2011) United Arab Emirates
• PMID: 21208155 (Publication Type: Journal Article, Review)

Chemical References

• Acetates
• Bile Acids and Salts
• Biomarkers
• GC 1 compound
• Hypolipidemic Agents
• Phenols
• Receptors, LDL
• Thyroid Hormones
• Triglycerides
• Cholesterol

Topics

• Acetates (therapeutic use)
• Animals
• Bile Acids and Salts (metabolism)
• Biomarkers (blood)
• Cholesterol (blood)
• Dyslipidemias (blood, drug therapy)
• Humans
• Hypolipidemic Agents (therapeutic use)
• Liver (drug effects, metabolism)
• Molecular Mimicry
• Phenols (therapeutic use)
• Receptors, LDL (metabolism)
• Thyroid Hormones (metabolism)
• Treatment Outcome
• Triglycerides (blood)